News

Phone interview research for patients diagnosed with Amyloid Light-Chain(AL), Transyretin (TTR), or Amyloid Protein (AA) Systemic Amyloidosis The purpose of this phone interview research study is to gather information about the symptoms and experiences of patients with Amyloid Light-Chain (AL),...

"Save one life and you're a hero, save one hundred lives and you're a nurse." This anonymous quote about the role of nurses in the medical profession embodies our decision to participate in the American Association of Heart Failure Nurses...

Much has been said about the need to put patients at the center of drug development. The Amyloidosis Research Consortium (ARC), is doing just that. The FDA's Patient-Focused Drug Development initiative is a commitment under the fifth authorization of the...

Guilherme José Jucá Calheiros carried the Olympic torch in Maceio (AL) Brazil. Guilherme is diagnosed with ATTR Familial Amyloidosis (FAP), which is a rare autosomal dominant amyloidosis disease caused by the deposition of abnormal transthyretin that results from a gene mutation....

The Phase 3 outcome study of CARDIO-TTR, evaluating patients with TTR amyloid cardiomyopathy through the IONIS-TTRRx program will not be initiated. The other IONIS-TTRRx studies are continuing and include the NEURO-TTR Phase 3 study and Dr. Merrill Benson’s investigator-initiated Phase...